{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/anticoagulation-oral/management/edoxaban/","result":{"pageContext":{"chapter":{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban","depth":2,"htmlHeader":"<!-- begin field eaa151d5-698d-4a21-94c0-eafec664c7b3 --><h2>Scenario: Edoxaban</h2><!-- end field eaa151d5-698d-4a21-94c0-eafec664c7b3 -->","summary":"Covers prescribing and management information for adults receiving edoxaban for use within its licensed indication.","htmlStringContent":"<!-- begin item 49092123-cf69-4b73-9e82-a42c98649846 --><!-- begin field 6860afca-2bff-4425-8903-acd900add833 --><p>From age 16 years onwards.</p><!-- end field 6860afca-2bff-4425-8903-acd900add833 --><!-- end item 49092123-cf69-4b73-9e82-a42c98649846 -->","topic":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78","topicId":"d64523b7-19f2-41a0-afd4-d1c0790cce30","topicName":"Anticoagulation - oral ","slug":"anticoagulation-oral","lastRevised":"January 2021","chapters":[{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2424a367-7b32-59ea-8783-9d80a1a68c3c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes"},{"id":"14f1139a-434d-530b-be52-9692e9271a76","slug":"update","fullItemName":"Update"}]},{"id":"67dfc47b-2285-596f-9f26-279a85f25dcc","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4b943e8-803b-51b4-a154-3a58c4bbaf1a","slug":"goals","fullItemName":"Goals"},{"id":"1a8fff43-5d5a-5e06-803b-ea61542c56a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a1c4ef1a-272a-56c2-bba9-b437e8b0e03d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"54bcfbdc-7506-5ca1-ae0c-e5ab55acb001","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2387aba8-f14a-5fc6-8335-485e08a6c959","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dd9aca34-523a-570a-bb3f-422e7bf450a7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications"}]},{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","fullItemName":"Management","slug":"management","subChapters":[{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban"},{"id":"e4a2d921-e87f-5760-a17a-271fefa9d1c4","slug":"dabigatran","fullItemName":"Scenario: Dabigatran"},{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban"},{"id":"015cbcc5-4efe-568f-9643-d7a22d37b286","slug":"rivaroxaban","fullItemName":"Scenario: Rivaroxaban"},{"id":"693e35a4-4b44-514c-847c-855a53793f98","slug":"warfarin","fullItemName":"Scenario: Warfarin"}]},{"id":"3d346e04-bfd5-53aa-9cbe-bee5c6a912bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"76dbe1dd-0d3b-50e8-9472-5af55550c77a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f762de3-78b6-55d7-b9bb-cc3f1cb77bea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c725a38-4d35-5fbd-bd5d-b48afc70e783","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2b9eb7d5-9bc8-5af8-b91f-75e9b1480d83","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33630559-9216-56bf-9890-6bbe997245bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51bd3b51-3e20-5f51-a925-74b2c904fd53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"54dbb8de-8bee-5c53-b63b-9645b55e6b5d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e58ddbbf-0db7-58a1-b092-48c4533aa55f","slug":"recommended-dose-treatment-duration","fullItemName":"Recommended dose and treatment duration","depth":3,"htmlHeader":"<!-- begin field c588007c-0455-4225-a92a-ea740838c155 --><h3>What is the recommended dose and duration of treatment for edoxaban?</h3><!-- end field c588007c-0455-4225-a92a-ea740838c155 -->","summary":null,"htmlStringContent":"<!-- begin item 10a3088d-330a-4c97-bb27-b559c3decfc3 --><!-- begin field 53e7f717-c088-459f-a600-4e8eb5c77880 --><ul><li><strong>For the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in people with at least one risk factor, such as congestive heart failure, hypertension, aged 75 years and over, diabetes mellitus, previous stroke or transient ischaemic attack:</strong><ul><li>The recommended dose is 60 mg once daily.</li><li>A reduced dose of 30 mg once daily is recommended if the person:<ul><li>Weighs 60 kg or less.</li><li>Has moderate or severe renal impairment (creatinine clearance [CrCl] 15–50 mL/minute).</li><li>Is receiving concurrent treatment with any of the following P-glycoprotein (P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#drug-interactions\">Drug interactions</a> for more information.</li></ul></li><li>Treatment is usually long term.</li></ul></li><li><strong>For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE:</strong><ul><li>The recommended dose is 60 mg once daily following initial use of parenteral anticoagulation for at least 5 days.</li><li>A reduced dose of 30 mg once daily is recommended if the person:<ul><li>Weighs 60 kg or less.</li><li>Has moderate or severe renal impairment (CrCl 15–50 mL/minute).</li><li>Is receiving concurrent treatment with any of following P-gp inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#drug-interactions\">Drug interactions</a> for more information.</li></ul></li><li>The duration of treatment should be individualized after careful assessment of the treatment benefit against the risk for bleeding:<ul><li>Short duration of treatment (at least 3 months) should be based on transient risk factors (for example, recent surgery, trauma, immobilization), and longer durations should be based on permanent risk factors.</li></ul></li></ul></li></ul><!-- end field 53e7f717-c088-459f-a600-4e8eb5c77880 --><!-- end item 10a3088d-330a-4c97-bb27-b559c3decfc3 -->","subChapters":[{"id":"6cfafb2a-9317-51e6-b424-1675203ece27","slug":"basis-for-recommendation-84f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 34ee89fb-a6be-4b25-a730-44188114bb2d --><h4>Basis for recommendation</h4><!-- end field 34ee89fb-a6be-4b25-a730-44188114bb2d -->","summary":null,"htmlStringContent":"<!-- begin item 84fd4c8e-2300-4bbc-a8e0-8fec45509377 --><!-- begin field f8351978-38c2-4427-8dec-05894da9870c --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field f8351978-38c2-4427-8dec-05894da9870c --><!-- end item 84fd4c8e-2300-4bbc-a8e0-8fec45509377 -->","subChapters":[]}]},{"id":"95b226a0-27d3-5c72-afe0-d6c60475281e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3ac6e641-8c67-49e6-8a13-3124f481f36e --><h3>What are the contraindications and cautions for edoxaban?</h3><!-- end field 3ac6e641-8c67-49e6-8a13-3124f481f36e -->","summary":null,"htmlStringContent":"<!-- begin item 927bd9ac-5cb4-402a-84bc-a85aff4b987e --><!-- begin field 40e4db90-89a4-45b6-b125-1a3ffe5245b8 --><ul><li><strong> Edoxaban is contraindicated in:</strong><ul><li>People with:<ul><li>Creatinine clearance (CrCl) less than 15 mL/minute.</li><li>Active bleeding.</li><li>Antiphospholipid syndrome — increased risk of recurrent thrombotic events.</li><li>Prosthetic heart valve and moderate to severe mitral stenosis — safety and efficacy not established.</li><li>Arteriovenous malformations.</li><li>Major intraspinal or intracerebral vascular abnormalities.</li><li>Uncontrolled severe hypertension.</li><li>Liver disease associated with coagulopathy and clinically relevant bleeding risk.</li></ul></li><li>People with a significant risk of major bleeding, such as:<ul><li>Current or recent gastrointestinal ulcer.</li><li>Oesophageal varices.</li><li>Recent brain or spinal injury.</li><li>Recent brain, spine, or ophthalmic surgery.</li><li>Recent intracranial haemorrhage.</li><li>Malignant neoplasm at high risk of bleeding.</li><li>Vascular aneurysm.</li></ul></li><li>Women who are pregnant or breastfeeding — the safety of edoxaban has not been established in these groups.</li></ul></li><li><strong>Edoxaban should be used with caution in the following groups:</strong><ul><li>People with:<br><ul><li>Moderate to severe renal impairment (CrCl 15–50 mL/minute) — <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#recommended-dose-treatment-duration\">dose reduction</a> is indicated (approximately 50% of edoxaban is excreted renally).</li><li>Body weight of 60 kg or less — <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#recommended-dose-treatment-duration\">dose reduction</a> is indicated (low body weight may increase plasma concentrations of edoxaban).</li></ul></li><li> People taking certain drugs, including:<ul><li>Strong inhibitors of P-glycoprotein (P-gp), such as ciclosporin, dronedarone, erythromycin, or ketoconazole — <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#recommended-dose-treatment-duration\">dose reduction</a> is indicated (plasma concentration of edoxaban is increased by these drugs).</li><li>Other drugs that can cause bleeding, such as nonsteroidal anti-inflammatory drugs (NSAIDs) — if concurrent treatment is unavoidable, close monitoring for signs of bleeding and anaemia is recommended. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#drug-interactions\">Drug interactions</a> for more information, and for information on other drug interactions of edoxaban.</li></ul></li></ul></li></ul><!-- end field 40e4db90-89a4-45b6-b125-1a3ffe5245b8 --><!-- end item 927bd9ac-5cb4-402a-84bc-a85aff4b987e -->","subChapters":[{"id":"662b61a2-371d-5082-b1b2-fc2fc46d28c9","slug":"basis-for-recommendation-acb","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 066f5dc9-cee6-417c-8138-3314ca973d4b --><h4>Basis for recommendation</h4><!-- end field 066f5dc9-cee6-417c-8138-3314ca973d4b -->","summary":null,"htmlStringContent":"<!-- begin item acb991df-7f61-4f01-af5a-ce7ac877fb1f --><!-- begin field bac688ad-b113-483d-b0ff-22bcf13b4598 --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>], the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>], and Drug Safety Updates issued by the Medicines and Healthcare products Regulatory Agency (MHRA): <em>Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2019a</a>] and <em>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</p><h5>Prosthetic heart valves and moderate to severe mitral stenosis</h5><ul><li>The manufacturer states that edoxaban has not been studied in people with mechanical heart valves, in people during the first 3 months after implantation of a bioprosthetic heart valve (with or without atrial fibrillation), or in people with moderate to severe mitral stenosis. Therefore, the use of edoxaban is not recommended in these groups of people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>].</li></ul><h5>Antiphospholipid syndrome</h5><ul><li>A clinical trial has shown an increased risk of recurrent thrombotic events associated with rivaroxaban compared with warfarin in people with antiphospholipid syndrome and a history of thrombosis; there may be a similar risk associated with other DOACs. The MHRA advises that DOACs are not recommended in people with antiphospholipid syndrome, particularly high-risk individuals who test positive for all three antiphospholipid tests — lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Continued treatment should be reviewed in these people to determine if appropriate and switching to a vitamin K antagonist (such as warfarin) should be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2019a</a>].</li></ul><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with edoxaban after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are also advised to use edoxaban with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</li></ul><h5>Renal function</h5><ul><li>Expert opinion in the European Heart Rhythm Association (EHRA) guideline is that approximately 50% of edoxaban is excreted renally. Exposure to edoxaban is substantially increased in people with renal insufficiency, leading to an increased risk of bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</li></ul><!-- end field bac688ad-b113-483d-b0ff-22bcf13b4598 --><!-- end item acb991df-7f61-4f01-af5a-ce7ac877fb1f -->","subChapters":[]}]},{"id":"172e9208-e65f-58de-86bd-148618c82684","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f57a3877-b374-4f3a-b846-1ff4b1bad151 --><h3>What are the adverse effects of edoxaban?</h3><!-- end field f57a3877-b374-4f3a-b846-1ff4b1bad151 -->","summary":null,"htmlStringContent":"<!-- begin item d9fff516-808f-431d-b7ea-054bc92d5cdf --><!-- begin field 8855b20b-ab9f-46ab-92d8-e6ed841b2e7b --><ul><li><strong>Bleeding is a common adverse effect of all anticoagulants, including edoxaban, </strong><strong>and it can occur in any part of the body.</strong><ul><li>Advise people taking edoxaban to:<ul><li>Seek immediate medical advice if spontaneous bleeding occurs and does not stop, or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, haemoptysis, subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li>Seek medical advice if they get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li><li>Get advice from a doctor or pharmacist before taking other medications, including over-the-counter medicines (such as nonsteroidal anti-inflammatory drugs) and herbal remedies, due to possible <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#drug-interactions\">drug interactions</a> with edoxaban.</li></ul></li><li>There is currently no reversal agent for edoxaban.</li></ul></li><li><strong>Other adverse effects of edoxaban include: </strong><ul><li>Common — anaemia, dizziness, gastrointestinal disorders, headache, pruritus, rash, nausea, and abnormal liver function tests.</li><li>Uncommon — thrombocytopenia, hypersensitivity, and urticaria. </li><li>Rare — anaphylactic reaction and allergic oedema.</li></ul></li></ul><!-- end field 8855b20b-ab9f-46ab-92d8-e6ed841b2e7b --><!-- end item d9fff516-808f-431d-b7ea-054bc92d5cdf -->","subChapters":[{"id":"478afce7-3c93-5ddb-b616-7d76915eca67","slug":"basis-for-recommendation-117","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ced8b95f-1b18-4db3-8778-3d34c3acfbe9 --><h4>Basis for recommendation</h4><!-- end field ced8b95f-1b18-4db3-8778-3d34c3acfbe9 -->","summary":null,"htmlStringContent":"<!-- begin item 11702743-42c1-4f68-b394-a0c0909ce9c1 --><!-- begin field 400c6052-166c-420d-bbcf-8d2f31f413c3 --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>], and the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>]. </p><h5>Risk of bleeding</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with edoxaban after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are also advised to use edoxaban with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment. The person should be counselled on the signs and symptoms of bleeding and encouraged to read the patient information leaflet [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</li><li>There is currently no reversal agent for edoxaban. Management of a bleeding complication in secondary care consists of stopping treatment and general haemostatic measures, such as mechanical compression, surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy), or platelets.</li></ul><!-- end field 400c6052-166c-420d-bbcf-8d2f31f413c3 --><!-- end item 11702743-42c1-4f68-b394-a0c0909ce9c1 -->","subChapters":[]}]},{"id":"bfe7177d-0ab5-5af2-ab9c-f70d50c37c26","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 82c32b02-f9ab-41a6-9635-679d4d6ebd56 --><h3>What are the key drug interactions for edoxaban?</h3><!-- end field 82c32b02-f9ab-41a6-9635-679d4d6ebd56 -->","summary":null,"htmlStringContent":"<!-- begin item cdce1651-1e47-45e4-b085-8bf242af1c18 --><!-- begin field 097e03d5-09b5-496a-b11c-7eb63f6f47b0 --><ul><li><strong>Key drug interactions with edoxaban include:</strong><ul><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— edoxaban is predicted to increase the risk of bleeding events when given with NSAIDs (such as ibuprofen).<ul><li>The manufacturer of edoxaban advises to avoid.</li><li>If concurrent use is indicated, monitor for signs of bleeding and anaemia.</li></ul></li><li><strong>Other anticoagulants, such as heparin, warfarin, apixaban, dabigatran, and rivaroxaban </strong>— there is an increased risk of bleeding if other anticoagulants are given with edoxaban.<ul><li>Avoid concurrent use except when switching to or from warfarin treatment. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#switching-anticoagulants\">Switching anticoagulants</a> for more information.</li></ul></li><li><strong>Antiplatelets, such as aspirin, clopidogrel, and ticagrelor </strong>— edoxaban is predicted to increase the risk of bleeding events when given with antiplatelet drugs. <ul><li>The manufacturer of edoxaban advises to avoid concurrent use.</li></ul><ul><li>If concurrent use is indicated, monitor for signs of bleeding and anaemia.</li></ul></li><li><strong>Strong inhibitors of P-glycoprotein (P-gp), such as ciclosporin, dronedarone, erythromycin, itraconazole, and ketoconazole </strong>— plasma concentration of edoxaban is increased by these drugs (edoxaban is a substrate for P-gp).<ul><li>The manufacturer advises that the <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#recommended-dose-treatment-duration\">dose of edoxaban</a> should be reduced to 30 mg daily during concurrent treatment with these drugs.</li><li>With mild to moderate P-gp inhibitors, such as quinidine, amiodarone, and verapamil, no dose reduction is required during concurrent treatment with edoxaban.</li></ul></li><li><strong>Strong inducers of P-gp, such as carbamazepine, phenytoin, rifampicin, and St John's Wort </strong>— plasma concentration of edoxaban may be reduced by these drugs.<ul><li>The manufacturer of edoxaban advises to avoid.</li><li>If concurrent use is indicated, monitor for signs of thrombosis.</li></ul></li><li><strong>Selective serotonin reuptake inhibitors (such as citalopram), serotonin norepinephrine re-uptake inhibitors (duloxetine), and venlafaxine </strong>— there is a possible increased risk of bleeding when edoxaban is given with these antidepressants.<ul><li>The manufacturer of edoxaban advises to avoid concurrent use. </li><li>If concurrent use is indicated, monitor for signs of bleeding and anaemia.</li></ul></li></ul></li><li>See the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"bf6bda62-14be-48b6-a3bd-a98d000d45b6\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"f811dbb2-4c9a-4436-be05-a98d000d462f\">British National Formulary</a> (BNF) for other possible drug interactions with edoxaban.</li></ul><!-- end field 097e03d5-09b5-496a-b11c-7eb63f6f47b0 --><!-- end item cdce1651-1e47-45e4-b085-8bf242af1c18 -->","subChapters":[{"id":"89c350b7-1bdf-5a92-8afe-67290724b395","slug":"basis-for-recommendation-939","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 40d8d410-cbd4-4572-92e5-d8f79c459bbd --><h4>Basis for recommendation</h4><!-- end field 40d8d410-cbd4-4572-92e5-d8f79c459bbd -->","summary":null,"htmlStringContent":"<!-- begin item 9390b1a0-beaf-443e-baa4-20ca99a5a8cd --><!-- begin field 422c6927-1122-4d7e-9f43-43b9368d21d8 --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 422c6927-1122-4d7e-9f43-43b9368d21d8 --><!-- end item 9390b1a0-beaf-443e-baa4-20ca99a5a8cd -->","subChapters":[]}]},{"id":"2fd5d14f-5a92-5d5c-b1ec-ef198e6ed13f","slug":"switching-anticoagulants","fullItemName":"Switching anticoagulants","depth":3,"htmlHeader":"<!-- begin field 528f3d38-614e-486b-8fba-8dc58dabe545 --><h3>How should I switch a person to or from another anticoagulant?</h3><!-- end field 528f3d38-614e-486b-8fba-8dc58dabe545 -->","summary":null,"htmlStringContent":"<!-- begin item baf8e396-e9df-4ff9-9014-d00c9498e64a --><!-- begin field efc46e5f-94cd-426d-8bb4-15a81b5a5b49 --><ul><li><strong>Switching from warfarin to edoxaban:</strong><ul><li>Stop warfarin, and measure the international normalized ratio (INR): <ul><li>If the INR is less than 2, start edoxaban.</li><li>If the INR is between 2 and 2.5, start edoxaban the next day.</li><li>If the INR is greater than 2.5, wait until the person's INR has dropped to less than 2 before starting edoxaban.</li></ul></li><li>The time taken for the person's INR to reach less than 2 will vary from person to person and will depend on what the person's initial INR level was.</li></ul></li><li><strong>Switching from edoxaban to warfarin:</strong><ul><li>Start warfarin, and reduce the dose of edoxaban:<ul><li>For people taking 60 mg of edoxaban, prescribe 30 mg once daily with warfarin.</li><li>For people taking 30 mg of edoxaban, prescribe 15 mg once daily with warfarin.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/warfarin/#starting-warfarin-treatment\">Starting warfarin treatment</a> for information on how to initiate warfarin treatment.</li></ul></li><li>Continue concurrent warfarin and edoxaban until the person's INR is at the target range (2 or more), then stop edoxaban.<ul><li>Most people should be able to achieve an INR of 2 or more within 14 days of concurrent administration of edoxaban and warfarin. </li><li>Measure the INR at least 3 times just prior to taking the daily dose of edoxaban during the first 14 days of concurrent treatment.</li><li>After 14 days it is recommended that edoxaban is discontinued and warfarin continued to be titrated to achieve an INR between 2–3.</li></ul></li><li>After treatment with edoxaban has stopped:<ul><li>Measure the INR after 24 hours to ensure adequate anticoagulation.</li><li>Monitor the person's INR closely (once a week) in the first month of warfarin treatment until the person has three consecutive stable INR values (for example between 2–3).</li></ul></li></ul></li><li><strong>Switching from edoxaban to</strong><strong> another direct-acting oral anticoagulant (DOAC):</strong><ul><li>Stop edoxaban, and start the new DOAC (apixaban, dabigatran, or rivaroxaban) when the next dose of edoxaban is due.<ul><li>In situations where higher than therapeutic plasma concentrations are expected, such as in people with impaired renal function, a longer interval in between DOACs is recommended.</li></ul></li></ul></li><li><strong>Switching from another DOAC to edoxaban:</strong><ul><li>Stop the initial DOAC (apixaban, dabigatran, or rivaroxaban), and start edoxaban when the next dose of the initial DOAC (apixaban, dabigatran, or rivaroxaban) is due.<ul><li>In situations where higher than therapeutic plasma concentrations are expected, such as in people with impaired renal function, a longer interval in between DOACs is recommended.</li></ul></li></ul></li></ul><!-- end field efc46e5f-94cd-426d-8bb4-15a81b5a5b49 --><!-- end item baf8e396-e9df-4ff9-9014-d00c9498e64a -->","subChapters":[{"id":"e25786e9-cb02-5b06-b9fc-b8ec7f8d76ea","slug":"basis-for-recommendation-60e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4f7fb0ff-af1f-475b-bfdb-bca840976992 --><h4>Basis for recommendation</h4><!-- end field 4f7fb0ff-af1f-475b-bfdb-bca840976992 -->","summary":null,"htmlStringContent":"<!-- begin item 60ea15e0-0ac3-4e0f-8324-e56bc83ff016 --><!-- begin field 58583287-c281-447e-81f9-c5376ae97340 --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>] and <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><h5>Switching from warfarin to edoxaban </h5><ul><li>The manufacturer of edoxaban advises switching from warfarin to edoxaban when the international normalized ratio (INR) is 2.5 or less [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>]. However, the European Heart Rhythm Association (EHRA) recommends that all direct-acting oral anticoagulants (DOACs) can be started when the INR is 2 or less [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</li></ul><h5>Switching from edoxaban to warfarin</h5><ul><li>The manufacturer of edoxaban states that 85% of people should be able to achieve an INR of 2 or more within 14 days of concurrent administration of edoxaban and warfarin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>].</li></ul><!-- end field 58583287-c281-447e-81f9-c5376ae97340 --><!-- end item 60ea15e0-0ac3-4e0f-8324-e56bc83ff016 -->","subChapters":[]}]},{"id":"8df20a0e-3133-557f-88e4-82af8aceb3e3","slug":"surgery-dental-treatment","fullItemName":"Surgery and dental treatment","depth":3,"htmlHeader":"<!-- begin field 61ddd26b-1a6c-42c4-8d84-e332c0401b7c --><h3>Should edoxaban be stopped if surgery or dental treatment is required?</h3><!-- end field 61ddd26b-1a6c-42c4-8d84-e332c0401b7c -->","summary":null,"htmlStringContent":"<!-- begin item 792e40bb-5384-4bda-a27a-97b675823cce --><!-- begin field 9c720431-97ca-40aa-a3d3-8737d7ddcf99 --><ul><li><strong>If the person needs to have surgery or any other invasive procedure, they may need to temporarily stop taking edoxaban. </strong>The decision to stop apixaban and when to stop it will depend on the person's risk of having a thromboembolic event and the bleeding risk associated with the procedure.</li><li><strong><strong>For most minor surgical procedures and those associated with a</strong> </strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#bleeding-risk\">minor bleeding risk</a></strong><strong>,</strong> it is recommended not to interrupt oral anticoagulation.<ul><li>In general, these procedures can be performed 12–24 hours after the last dose of edoxaban is taken.</li><li>It may be practical to have the intervention scheduled 18–24 hours after the last dose of edoxaban is taken, then restart apixaban 6 hours later. This means that one dose of edoxaban may be missed.</li></ul></li><li><strong>For procedures with a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#bleeding-risk\">low bleeding risk</a>, </strong>edoxaban should be stopped at least 24 hours before the procedure.<ul><li>If the person has a creatinine clearance (CrCl) between 15–29 mL/min, edoxaban should be stopped at least 36 hours before the procedure.</li></ul></li><li><strong>For procedures with a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#bleeding-risk\">high bleeding risk</a>,</strong> edoxaban should be stopped at least 48 hours before the procedure.</li></ul><!-- end field 9c720431-97ca-40aa-a3d3-8737d7ddcf99 --><!-- end item 792e40bb-5384-4bda-a27a-97b675823cce -->","subChapters":[{"id":"5811641e-7976-5e0b-9714-8a43426d9c9e","slug":"bleeding-risk","fullItemName":"Bleeding risk","depth":4,"htmlHeader":"<!-- begin field 214595c4-b46f-4190-b9aa-acb001656067 --><h4>Bleeding risk</h4><!-- end field 214595c4-b46f-4190-b9aa-acb001656067 -->","summary":null,"htmlStringContent":"<!-- begin item fd08f618-3cae-4522-8b5a-41b41fcd1a0e --><!-- begin field 7b4d2b46-e8ca-47c9-a8ce-acb001656067 --><ul><li><strong>Treatments with minor bleeding risk include:</strong><ul><li>Dental interventions, such as extraction of 1 to 3 teeth, periodontal surgery, incision of abscess, and implant positioning.</li><li>Cataract or glaucoma interventions.</li><li>Endoscopy without surgery.</li><li>Minor surgery, such as abscess incision and small dermatologic excisions.</li></ul></li><li><strong>Treatments with low bleeding risk include:</strong><ul><li>Endoscopy with biopsy.</li><li>Prostate or bladder biopsy.</li><li>Electrophysiological study or radiofrequency catheter ablation for supraventricular tachycardia (including left-sided ablation via single trans-septal puncture).</li><li>Angiography.</li><li>Pacemaker or implantable cardioverter defibrillator (ICD) implantation (unless complex anatomical setting, for example congenital heart disease).</li></ul></li><li><strong>Treatments with high bleeding risk include:</strong><ul><li>Complex endoscopy, such as polypectomy and endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy.</li><li>Spinal or epidural anaesthesia.</li><li>Lumbar diagnostic puncture.</li><li>Thoracic surgery.</li><li>Abdominal surgery.</li><li>Major orthopaedic surgery.</li><li>Liver biopsy.</li><li>Transurethral prostate resection.</li><li>Kidney biopsy.</li><li>Extracorporeal shockwave lithotripsy (ESWL).</li></ul></li><li><strong>Treatments with high bleeding risk <em>and</em> increased thromboembolic risk include:</strong><ul><li>Complex left-sided ablation (pulmonary vein isolation, some VT ablations).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>]</p><!-- end field 7b4d2b46-e8ca-47c9-a8ce-acb001656067 --><!-- end item fd08f618-3cae-4522-8b5a-41b41fcd1a0e -->","subChapters":[]},{"id":"b3a8eec1-2c95-53bf-ab9a-c5a6b6cad8c7","slug":"basis-for-recommendation-bf6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f333e032-3cbd-40c2-977e-9038403a03c2 --><h4>Basis for recommendation</h4><!-- end field f333e032-3cbd-40c2-977e-9038403a03c2 -->","summary":null,"htmlStringContent":"<!-- begin item bf66cc16-f7d8-4c5b-8770-6c4ed6f68883 --><!-- begin field 84bd5bc3-5f89-434b-bcc5-1eef6613ea1e --><p>These recommendations are based on the manufacturer's Summary of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>] and <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><h5>Minor bleeding risk</h5><ul><li>The European Heart Rhythm Association (EHRA) recommends not to interrupt oral anticoagulation for most minor surgical procedures and those procedures where bleeding is easily controllable. </li></ul><h5>Low bleeding risk</h5><ul><li>For invasive procedures with a low bleeding risk (that is, low frequency of bleeding and/or minor impact of bleeding), edoxaban should be discontinued at least 24 hours before the procedure in most people, and at least 36 hours if creatinine clearance (CrCl) is 15–29 mL/minute.</li></ul><h5>High bleeding risk</h5><ul><li>For invasive procedures that carry a high risk for major bleeding (that is, with a high frequency of bleeding and/or important clinical impact), the EHRA recommends taking the last direct oral anticoagulant (DOAC) dose 48 hours or longer before surgery.</li></ul><!-- end field 84bd5bc3-5f89-434b-bcc5-1eef6613ea1e --><!-- end item bf66cc16-f7d8-4c5b-8770-6c4ed6f68883 -->","subChapters":[]}]},{"id":"725c810a-34df-598c-b6cd-47e71435bac7","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 0fffb12d-f651-48c5-ba09-0cc654cb152b --><h3>How should I monitor a person taking edoxaban?</h3><!-- end field 0fffb12d-f651-48c5-ba09-0cc654cb152b -->","summary":null,"htmlStringContent":"<!-- begin item d9689aa1-8ab7-4633-91f0-623868faf1ca --><!-- begin field 7a156a82-c235-4638-8cff-2938de5a32b4 --><p><strong>There is no need to monitor the international normalized ratio (INR) in people taking edoxaban; however, regular follow up and monitoring is recommended.</strong></p><ul><ul><li><strong>At the start of treatment, </strong>baseline clotting screen, renal and liver function tests, and a full blood count should be performed.</li><li><strong>Once treatment has started, </strong>review the person on a regular basis, preferably after 1 month initially and at least every 3 months thereafter. Follow-up intervals may be longer (up to every 6 months) or shorter (for example every month) depending on patient factors, such as renal function, age, and comorbidities.</li><li><strong>During a review:</strong><ul><li>Assess adherence to treatment.</li><li>Look for signs of bleeding or anaemia. </li><li>Ask about other <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#adverse-effects\">adverse effects</a> of edoxaban.</li><li>Assess for features of thromboembolic events, such as symptoms of stroke, or breathlessness (which may suggest a pulmonary embolism). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a> and <a class=\"topic-reference external-reference\" href=\"/topics/pulmonary-embolism/\">Pulmonary embolism</a> for more information.</li><li>Ask about the use of other medications, including over-the-counter (OTC) products, to identify possible <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#drug-interactions\">drug interactions</a> with edoxaban.</li><li>Assess and minimize modifiable risk factors for bleeding, such as uncontrolled hypertension, medication predisposing for bleeding (such as aspirin), and excessive alcohol intake.</li><li>Give appropriate information and advice on edoxaban treatment. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#advice-to-patients\">Advice for patients</a> for more information.</li></ul></li><li><strong>Repeat the renal and liver function tests and the full blood count yearly for most people.</strong><ul><li>If the person is frail or older than 75 years, repeat the blood tests every 6 months.</li><li>If the person has a creatinine clearance (CrCl) less than 60 mL/minute, the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.</li><li>If the person has an intercurrent illness that may impact renal or hepatic function, repeat renal and liver function tests as needed.</li></ul></li><li><strong>Manage any problems identified during a review or from blood test results. </strong><ul><li>If renal function has declined, review treatment — edoxaban may need to be stopped or a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#recommended-dose-treatment-duration\">lower dose</a> may be required. </li><li>If there is an unexplained fall in haemoglobin and/or haematocrit, occult bleeding may be present (edoxaban can cause bleeding from any site) — stop treatment with edoxaban and seek specialist advice.</li></ul></li><li><strong>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#monitoring-during-the-covid-19-pandemic\">Monitoring during Covid-19 pandemic</a> for more monitoring advice.</strong></li></ul></ul><!-- end field 7a156a82-c235-4638-8cff-2938de5a32b4 --><!-- end item d9689aa1-8ab7-4633-91f0-623868faf1ca -->","subChapters":[{"id":"171b7df6-5472-5cef-b76c-da90c11e2a75","slug":"basis-for-recommendation-21e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ee7abdd6-fcf3-48ab-9740-a8a6a0bee306 --><h4>Basis for recommendation</h4><!-- end field ee7abdd6-fcf3-48ab-9740-a8a6a0bee306 -->","summary":null,"htmlStringContent":"<!-- begin item 21ee9264-f043-45a5-904f-f804d06c34b1 --><!-- begin field 6e1798b5-d2f0-4921-9b32-fc6c63db13a6 --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>], the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update<em> Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</p><h5>Regular monitoring of edoxaban treatment</h5><ul><li>No routine anticoagulant monitoring is required during treatment with edoxaban — international normalized ratio (INR) tests give misleading results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>]. However, regular follow up and monitoring is recommended. </li><li>The European Heart Rhythm Association (EHRA) states that treatment with DOACs requires vigilance due to potentially severe complications, especially as the target patient population tends to be frail and of older age. According to the EHRA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>]:<br><ul><li>DOACs have an improved efficacy/safety ratio, a predictable anticoagulant effect without the need for routine coagulation monitoring, and fewer drug interactions than warfarin. However, treatment should be reviewed on a regular basis, preferably after 1 month initially and at least every 3 months thereafter. As clinical experience with these medications grows, follow-up intervals may become longer, based on individual (patient-specific) or local (centre-specific) factors. (The EHRA guideline gives a recommended follow-up interval of 1–6 months.)</li><li>The absence of a need for routine plasma level monitoring means that people taking DOACs are likely to be less frequently seen for follow-up appointments than people on warfarin treatment. Regular follow-up assessment is useful, especially for people with comorbidities (such as renal failure, older age, multiple comorbidities, or frailty).</li></ul></li></ul><h5>Renal function tests</h5><ul><li>Regular renal function tests are required as approximately 50% of edoxaban is excreted renally. Exposure to edoxaban is substantially increased in people with renal insufficiency, leading to an increased risk of bleeding. The EHRA advises that renal function should be monitored every 6 months if the person is aged over 75 years or frail, or more frequently if the creatinine clearance (CrCl) is less than 60 mL/minute [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</li></ul><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with edoxaban after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are advised to use edoxaban with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment. People should be counselled on the signs and symptoms of bleeding and encouraged to read the patient information leaflet [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</li><li>The SPCs and the BNF state that, as with other anticoagulants, people taking edoxaban should be carefully monitored for signs of bleeding, and treatment should be discontinued if bleeding occurs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field 6e1798b5-d2f0-4921-9b32-fc6c63db13a6 --><!-- end item 21ee9264-f043-45a5-904f-f804d06c34b1 -->","subChapters":[]}]},{"id":"7c474d1a-f214-53d2-8381-75376a9c260a","slug":"monitoring-during-the-covid-19-pandemic","fullItemName":"Monitoring during the Covid-19 pandemic","depth":3,"htmlHeader":"<!-- begin field 3cdcd34e-5fe2-487d-8a54-acb401762b5d --><h3>How should I monitor a person taking edoxaban during the COVID-19 pandemic?</h3><!-- end field 3cdcd34e-5fe2-487d-8a54-acb401762b5d -->","summary":null,"htmlStringContent":"<!-- begin item 29dda413-b4a2-448e-bacb-97d912f65cc1 --><!-- begin field 3fc1c355-e2ca-4e28-bdcf-acb401762b5d --><ul><li><strong>When monitoring a person taking edoxaban during the COVID-19 pandemic, remember that:</strong><br><ul><li>Direct-acting oral anticoagulants (DOACs), such as edoxaban, may <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#drug-interactions\">interact</a> with other medicines, including antibacterials and antivirals. Follow the advice in the manufacturer's Summary of Product Characteristics (SPC), available on the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"bf6bda62-14be-48b6-a3bd-a98d000d45b6\">electronic Medicines Compendium</a> (eMC) website, to minimize the risk of potential interactions.</li><li>If switching from warfarin to edoxaban, stop warfarin before starting edoxaban, to reduce the risk of over-anticoagulation and bleeding. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#switching-anticoagulants\">Switching anticoagulants</a> for more information.</li></ul></li></ul><!-- end field 3fc1c355-e2ca-4e28-bdcf-acb401762b5d --><!-- end item 29dda413-b4a2-448e-bacb-97d912f65cc1 -->","subChapters":[{"id":"4e150292-c0cb-54c4-855b-95e734f1147e","slug":"basis-for-recommendation-325","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 198964bc-6ddf-4024-ae78-acb401762b5d --><h4>Basis for recommendation</h4><!-- end field 198964bc-6ddf-4024-ae78-acb401762b5d -->","summary":null,"htmlStringContent":"<!-- begin item 325d25b0-94c9-4010-8f8a-cfc854699966 --><!-- begin field 327b867f-35ab-4cd4-85d1-acb401762b5d --><p>This recommendation is based on the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020b</a>].</p><!-- end field 327b867f-35ab-4cd4-85d1-acb401762b5d --><!-- end item 325d25b0-94c9-4010-8f8a-cfc854699966 -->","subChapters":[]}]},{"id":"a9769c8c-1613-50a3-8c00-0c1d08b7df7c","slug":"managing-dosing-errors","fullItemName":"Managing dosing errors","depth":3,"htmlHeader":"<!-- begin field 8df54d02-f0d7-4a1b-a798-87184d2e2c98 --><h3>How should I manage dosing errors in someone taking edoxaban?</h3><!-- end field 8df54d02-f0d7-4a1b-a798-87184d2e2c98 -->","summary":null,"htmlStringContent":"<!-- begin item 32a975c5-3fdf-41d0-a8bb-85b1a45593f3 --><!-- begin field 5e7988d3-be13-4ea5-a601-d139bdcd0324 --><ul><li><strong>If the person has missed a dose of edoxaban, </strong>the forgotten dose may be taken until half of the dosing interval has passed.<ul><li>This means that the forgotten dose can be taken up until 12 hours after the scheduled intake. After this time point, the dose should be skipped and the next scheduled dose should be taken.</li><li>The 12-hour interval may be extended in people with a high stroke risk.</li></ul></li><li><strong>If the person has taken a double dose of edoxaban, </strong>they should take the next dose as normal the following day.</li><li><strong>If the person is uncertain whether they have taken their dose,</strong> management will depend on their thrombotic risk:<ul><li>If thrombotic risk is high (CHA2DS2-VASc score greater than 3), it may generally be advisable to take another dose and then continue the planned dose regimen.</li><li>If thrombotic risk is low (CHA2DS2-VASc score less than 2), it is recommended that they wait until the time of their next scheduled dose.</li></ul></li></ul><!-- end field 5e7988d3-be13-4ea5-a601-d139bdcd0324 --><!-- end item 32a975c5-3fdf-41d0-a8bb-85b1a45593f3 -->","subChapters":[{"id":"5de12057-548c-5b4e-a1d1-a42e487b05db","slug":"basis-for-recommendation-6bd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e0bbf83c-1939-463a-9fce-fb50ebd33d37 --><h4>Basis for recommendation</h4><!-- end field e0bbf83c-1939-463a-9fce-fb50ebd33d37 -->","summary":null,"htmlStringContent":"<!-- begin item 6bd6fb13-5545-4a5a-8c2f-40ad14dd9cff --><!-- begin field f103c654-6d57-4e32-acdf-a6361540360e --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><!-- end field f103c654-6d57-4e32-acdf-a6361540360e --><!-- end item 6bd6fb13-5545-4a5a-8c2f-40ad14dd9cff -->","subChapters":[]}]},{"id":"bdc1cc2e-eb6f-5dc8-94be-5a46f1bc9bf2","slug":"advice-to-patients","fullItemName":"Advice to patients","depth":3,"htmlHeader":"<!-- begin field eb34274c-4dfa-4e9c-a1d9-8e18f71ae9bd --><h3>What advice should I give a person who is taking edoxaban?</h3><!-- end field eb34274c-4dfa-4e9c-a1d9-8e18f71ae9bd -->","summary":null,"htmlStringContent":"<!-- begin item e1082e39-b71a-4231-842a-5eafc9ca758b --><!-- begin field 73c6668a-ac6a-4fe1-b182-b5f137f129cb --><ul><li><strong>Advise the person taking edoxaban:</strong><ul><li>That although (unlike warfarin) there is no need to have regular blood tests to monitor the international normalized ratio (INR), they will still require regular <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#monitoring\">monitoring</a>, blood tests, and review of their treatment.</li><li>On the importance of a regular dosing schedule.<ul><li>The anticoagulant effect of edoxaban reduces 12–24 hours after the last dose is taken; therefore, it is important to take edoxaban as directed or the person is at increased risk of a thromboembolic event.</li><li>They should not miss doses (or take additional doses) without advice from a healthcare professional.</li></ul></li><li>That they should seek immediate medical advice:<ul><li>If spontaneous bleeding occurs and does not stop or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, haemoptysis, subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li>If they get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li><li>If they experience difficulty breathing, increased breathing rate, or chest pain (which could be symptoms of pulmonary embolism).</li></ul></li><li>That they should also seek medical advice:<ul><li>If there have been <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#managing-dosing-errors\">dosing errors</a> (for example, a missed dose or if a double dose has been taken).</li><li>Before taking other medications, including over-the-counter medicines (such as nonsteroidal anti-inflammatory drugs) and herbal remedies, due to possible <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#drug-interactions\">drug interactions</a> with edoxaban.</li><li>If they experience other <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/dabigatran/#adverse-effects\">adverse effects</a> of edoxaban.</li></ul></li><li>That they may have to stop edoxaban treatment temporarily for certain <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/edoxaban/#surgery-dental-treatment\">surgical and dental treatments</a>.</li><li>To read the manufacturer's <a href=\"https://www.medicines.org.uk/emc/product/6905/pil\" data-hyperlink-id=\"e7074f8e-b101-46d1-a5e2-acb300c26292\">patient information leaflet</a>, if they have not already.</li><li>To carry a Lixiana® Patient Alert Card at all times. These are contained in each UK tablet pack and can also be printed off from the electronic Medicines Compendium (eMC) website (<a href=\"https://www.medicines.org.uk/emc/rmm/227/Document\" data-hyperlink-id=\"14a196d0-0b5c-480f-8c61-acb0015148c6\">www.medicines.org.uk</a>).</li></ul></li></ul><!-- end field 73c6668a-ac6a-4fe1-b182-b5f137f129cb --><!-- end item e1082e39-b71a-4231-842a-5eafc9ca758b -->","subChapters":[{"id":"f87d64dd-f57d-5ec3-a815-5f5b0058db72","slug":"basis-for-recommendation-836","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9e7715ba-bb53-4feb-9ca8-5ee57d0631cc --><h4>Basis for recommendation</h4><!-- end field 9e7715ba-bb53-4feb-9ca8-5ee57d0631cc -->","summary":null,"htmlStringContent":"<!-- begin item 8361ab68-89aa-44e5-b8c8-d6cf6b9ec562 --><!-- begin field 1c8d13ee-2e0f-4086-946c-87729353b723 --><p>These recommendations are based on the manufacturer's Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2021b</a>] and <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><!-- end field 1c8d13ee-2e0f-4086-946c-87729353b723 --><!-- end item 8361ab68-89aa-44e5-b8c8-d6cf6b9ec562 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}